Transactions
11
Insider / IDEXX LABORATORIES INC /DE
Peacock Karen
Director at IDEXX LABORATORIES INC /DE
- Company
- IDEXX LABORATORIES INC /DE
- First filing on record
- December 3, 2025
- Latest trade on record
- July 29, 2026
- SEC filings
- EDGAR ↗
Peacock Karen, Director at IDEXX LABORATORIES INC /DE, has disclosed 11 transactions in DBX, IDXX since December 3, 2025: 0 purchases (0 open-market buys) and 4 sales, worth about $283K at the reported prices. The latest was filed July 31, 2026, 2 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
4
Avg. disclosure lag
2.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Peacock Karen made no purchases and 4 sales worth $283K, plus 7 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Peacock Karen has traded 1 stock on record; the largest by dollars is DBX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 8 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 5 | 10,162 | — |
| S | Open-market sale | 4 | 10,000 | $283K |
| M | Option exercise or conversion | 2 | 202 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 9 | 0 | 4 · $283K |
| 2025 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| DBX | Sell S | July 29, 2026 | July 31, 2026 | 2d | 2,000 | $33 | $66K | 10b5-1 plan | Form 4 ↗ | |
| DBX | Sell S | July 7, 2026 | July 9, 2026 | 2d | 2,000 | $29 | $58K | 10b5-1 plan | Form 4 ↗ | |
| DBX | Other A | May 21, 2026 | May 26, 2026 | 5d | 9,071 | — | — | late | Form 4 ↗ | |
| DBX | Sell S | May 15, 2026 | May 19, 2026 | 4d | 4,000 | $27 | $106K | 10b5-1 plan | Form 4 ↗ | |
| IDXX | Other A | May 12, 2026 | May 14, 2026 | 2d | 234 | — | — | derivative | Form 4 ↗ | |
| IDXX | Other A | May 12, 2026 | May 14, 2026 | 2d | 525 | — | — | derivative | Form 4 ↗ | |
| IDXX | Option / conversion M | May 7, 2026 | May 11, 2026 | 4d | 101 | — | — | derivative | Form 4 ↗ | |
| IDXX | Option / conversion M | May 7, 2026 | May 11, 2026 | 4d | 101 | — | — | Form 4 ↗ | ||
| DBX | Sell S | March 11, 2026 | March 13, 2026 | 2d | 2,000 | $27 | $53K | 10b5-1 plan | Form 4 ↗ | |
| IDXX | Other A | December 1, 2025 | December 3, 2025 | 2d | 231 | — | — | derivative | Form 4 ↗ | |
| IDXX | Other A | December 1, 2025 | December 3, 2025 | 2d | 101 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 31, 2026 | Form 4 | 0001786299-26-000009 | 1 | published | EDGAR ↗ |
| July 9, 2026 | Form 4 | 0001786299-26-000008 | 1 | published | EDGAR ↗ |
| May 26, 2026 | Form 4 | 0001786299-26-000006 | 1 | published | EDGAR ↗ |
| May 19, 2026 | Form 4 | 0001786299-26-000004 | 1 | published | EDGAR ↗ |
| May 14, 2026 | Form 4 | 0000874716-26-000105 | 2 | published | EDGAR ↗ |
| May 11, 2026 | Form 4 | 0000874716-26-000086 | 2 | published | EDGAR ↗ |
| March 13, 2026 | Form 4 | 0001786299-26-000002 | 1 | published | EDGAR ↗ |
| December 3, 2025 | Form 4 | 0000874716-25-000170 | 2 | published | EDGAR ↗ |
Other insiders at IDEXX LABORATORIES INC /DE
- Houston Andrew Director 51 rows
- Erickson Michael G Executive Vice President 35 rows
- Schubach Sarah Elizabeth Chief Accounting Officer 32 rows
- FENNELL GEORGE Executive Vice President 27 rows
- Hunt Nimrata Executive Vice President 25 rows
- MAZELSKY JONATHAN JAY President and CEO 25 rows
- Emerson Andrew EVP, CFO and Treasurer 18 rows
- Campbell Lisa M Director 15 rows
- Schreck Michael Executive Vice President 15 rows
- Underberg Sharon E. EVP, GC & Corporate Secretary 14 rows
Everyone on file, with contracts and lobbying under the company's name: IDEXX LABORATORIES INC /DE.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 8 | 11 | December 3, 2025 | July 31, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.